Product Review - Newly approved treatment for HIV-1 infection

This review discusses the evidence in support of the use of the newly approved (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF), a once-daily single-tablet regimen for the treatment of HIV-1 infection.

Independent expert commentary has been provided by Dr Darren Russell.

Please login below to download this issue (PDF)